AnaptysBio Inc Stock
AnaptysBio Inc Stock
We can see a decrease in the price for AnaptysBio Inc. Compared to yesterday it has lost -€0.400 (-1.050%).
With 24 Buy predictions and not a single Sell prediction AnaptysBio Inc is an absolute favorite of our community.
As a result the target price of 43 € shows a slightly positive potential of 14.36% compared to the current price of 37.6 € for AnaptysBio Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for AnaptysBio Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | -1.050% | 7.955% | 11.765% | 74.312% | 208.943% | 43.939% | 95.122% |
| NanoViricides Inc. | 1.770% | 29.032% | -25.466% | -13.669% | -20.000% | -14.712% | -58.904% |
| Actinium Pharmaceuticals Inc. | -2.280% | 3.635% | 12.066% | -2.466% | 6.516% | -87.921% | -86.674% |
| Immunic Inc. | 1.560% | 2.852% | -7.235% | -53.543% | -42.928% | -48.961% | -96.128% |
Comments
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
News
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6
